Stem cell exosome treatment for congenital myasthenic syndrome
Part of Brain & nervous system, Genetic & congenital clinical trials.
This trial tests a treatment made from stem cell exosomes (tiny particles that may help repair cells) for people with congenital myasthenic syndrome, a muscle-weakening condition. It aims to see if this treatment is safe and could improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with congenital myasthenic syndrome by a doctor.
- You must be able to give permission to join the trial, or have a parent or guardian who can.
- You must be able to travel to the treatment location.
- You cannot be pregnant at the time of screening.
- You cannot have active cancer at the screening visit.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment using exosomes (tiny particles from stem cells) given through a vein to people who recently had an ischemic stroke. It aims to see if this treatment is safe and helps improve recovery.
This study tests a new treatment using special cells (stem cells) and their tiny particles (exosomes) to see if they are safe and help improve symptoms. It is for people with spinocerebellar ataxia, a condition that affects movement and coordination.
This trial tests a new drug made from stem cell exosomes (CB-Exo-A600) to see if it can help people with mild to moderate Alzheimer's disease. It aims to slow down symptoms and improve quality of life.
This trial tests whether exosomes from stem cells can help people whose peritoneal dialysis is no longer working well. It may improve fluid removal and reduce symptoms like swelling.
This study tests a new therapy made from donor stem cells that may help repair damaged muscles, bones, tendons, and joints. It is for people whose injuries or degenerative conditions have not healed on their own.
This early-stage study (Phase 1) tests whether a tiny dose given through the nose is safe for people who have had a stroke. It uses exosomes made from adult umbilical cord stem cells, mainly to look for side effects and dosing safety.
Hear when a new Congenital Myasthenic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.